Literature DB >> 10359339

Interobserver agreement for grating acuity and letter acuity assessment in 1- to 5.5-year-olds with severe retinopathy of prematurity.

E M Harvey1, V Dobson, B Tung, G E Quinn, R J Hardy.   

Abstract

PURPOSE: To evaluate interobserver test-retest reliability of the Teller Acuity Card procedure for assessment of grating acuity at ages 1, 2, 3.5, 4.5, and 5.5 years, for HOTV letter acuity at 3.5 and 4.5 years, and for Early-Treatment Diabetic Retinopathy Study (ETDRS) letter acuity at 5.5 years in the multicenter study of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP).
METHODS: Subjects were the 73 participants in the CRYO-ROP study who had acuity assessed at one or more ages by two of the seven study visual acuity testers as part of a quality control procedure. All subjects had birth weights of less than 1251 g, and all had severe (threshold) ROP in one or both eyes.
RESULTS: For sighted eyes, interobserver agreement for grating acuity (across all five test ages) was 0.5 octave or better in 57% of eyes and 1.0 octave or better in 85% of eyes. Interobserver agreement for letter acuity (3.5-, 4.5-, and 5.5-year test ages) was 0.5 octave or better in 71% of eyes and 1.0 octave or better in 93% of eyes. For all eyes (sighted and blind), Kendall rank correlation coefficients (Tau) were 0.86, 0.83, and 0.94 for grating, HOTV, and ETDRS acuity, respectively. Kappa statistics on data from all eyes indicated excellent interobserver agreement for grating, HOTV, and ETDRS acuity (0.73, 0.80, and 0.84, respectively). Interobserver agreement was not related to age or to severity of retinal residua of ROP.
CONCLUSIONS: Excellent interobserver agreement for grating acuity measurements and for letter acuity measurements was obtained. Results suggest that with careful training and implementation of quality control procedures, high reliability of visual acuity results is possible in clinical populations of young children.

Entities:  

Mesh:

Year:  1999        PMID: 10359339

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Evaluating reading acuity and speed in children with microstrabismic amblyopia using a standardized reading chart system.

Authors:  E Stifter; G Burggasser; E Hirmann; A Thaler; W Radner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-08       Impact factor: 3.117

2.  Development of a quantitative method to measure vision in children with chronic cortical visual impairment.

Authors:  W V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2001

3.  Visual function in infants with antenatal Zika virus exposure.

Authors:  Andrea A Zin; Irena Tsui; Julia D Rossetto; Stephanie L Gaw; Luiza M Neves; Olivia A Zin; Lorena Haefeli; Joel Carlos Barros Silveira Filho; Kristina Adachi; Marcos Vinicius da Silva Pone; Sheila Moura Pone; Natalia Molleri; Jose Paulo Pereira; Rubens Belfort; Vaithilingaraja Arumugaswami; Zilton Vasconcelos; Patricia Brasil; Karin Nielsen-Saines; Maria Elisabeth Lopes Moreira
Journal:  J AAPOS       Date:  2018-10-22       Impact factor: 1.220

4.  Current concepts in the management of amblyopia.

Authors:  Blanca Ruiz de Zárate; Jaime Tejedor
Journal:  Clin Ophthalmol       Date:  2007-12

5.  Amblyopia treatment outcomes after screening before or at age 3 years: follow up from randomised trial.

Authors:  C Williams; K Northstone; R A Harrad; J M Sparrow; I Harvey
Journal:  BMJ       Date:  2002-06-29

6.  Reliability and Validity of Gaze-Dependent Functional Vision Space: A Novel Metric Quantifying Visual Function in Infantile Nystagmus Syndrome.

Authors:  Tawna L Roberts; Kristi N Kester; Richard W Hertle
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

7.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.